By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Wilex AG 

Grillparzerstrasse 10

81675 Munich  Bavaria    Germany
Phone: 49-0-89-41-31-38-0 Fax: 49-0-89-41-31-38-99


SEARCH JOBS



Segment
Drug Discovery





Company News
Wilex AG (WL6.DE): Subsidiary Heidelberg Pharma Signs Exclusive Multi-Target Research Agreement With Takeda (TKPYY) For The Development Of Antibody Targeted Amanitin Conjugates 6/20/2017 11:48:33 AM
Wilex AG (WL6.DE) Release: Company Signs Antibody License Agreement With Telix Pharma 1/16/2017 8:58:58 AM
Embattled Wilex AG (WL6.DE) Sells Unnamed Tumor Drug To Roche (RHHBY) For $65.8M 10/14/2014 6:19:31 AM
RedHill Biopharma Ltd. (RDHL) Acquires Phase 2 Oncology Drug MESUPRON® From Wilex AG (WL6.DE) 6/30/2014 7:59:22 AM
Wilex AG (WL6.DE) Sends Back Some Promising Drugs To UCB, Inc. (UCBJF.PK) In Effort To Stay Alive 5/22/2014 7:36:33 AM
Wilex AG (WL6.DE) Nosedives As Company Cuts 80 Percent Of Workers 1/30/2014 7:44:53 AM
Wilex AG (WL6.DE) Restructures, Cuts Jobs 12/5/2012 8:32:58 AM
Wilex AG (WL6.DE)'s Kidney Cancer Drug Fails in Late Stage Trial 10/17/2012 8:27:10 AM
Prometheus Laboratories Inc. Obtains Exclusive US Commercialization Rights for RENCAREX(R) from Wilex AG; Wilex to Receive $19 Million Upfront 5/2/2011 7:00:06 AM
Wilex AG's Redectane(R) Meets Both Endpoints Specificity And Sensitivity With Superiority Over CT In Its Pivotal Phase III Trial 5/19/2010 8:11:03 AM
12
//-->